Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis Healthcare's EBIT per Share for the
three
months ended in Jun. 2026 was ₹4.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹14.50.
During the past 12 months, the average EBIT per Share Growth Rate of Metropolis Healthcare was 42.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 12.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -0.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Metropolis Healthcare's EBIT per Share or its related term are showing as below:
NSE:METROPOLIS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.9 Med: 10.3 Max: 18.9
Current: 12.4
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Metropolis Healthcare was 18.90% per year. The lowest was -10.90% per year. And the median was 10.30% per year.
NSE:METROPOLIS's 3-Year EBIT Growth Rate is ranked worse than 52.15% of 163
companies
in the Medical Diagnostics & Research industry
Industry Median: 13
vs NSE:METROPOLIS: 12.40
Metropolis Healthcare (NSE:METROPOLIS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Metropolis Healthcare EBIT per Share Related Terms
Metropolis Healthcare EBIT per Share Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a EBIT per Share of ₹14.50 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Metropolis Healthcare and its competitors. According to the industry distribution chart, Metropolis Healthcare ranks #85 out of 163 companies in the Medical Diagnostics & Research industry, placing it in the top 52.1%.
Is Metropolis Healthcare's EBIT per Share too high?
Metropolis Healthcare's current EBIT per Share is ₹14.50. Based on the distribution chart, Metropolis Healthcare ranks #85 out of 163 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Metropolis Healthcare has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #85 out of 163 companies for EBIT per Share. This places Metropolis Healthcare in the lower half of its industry. The industry median EBIT per Share is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.00, based on 163 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current EBIT per Share is ₹14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹599.61, compared to a current price of ₹552.40 — trading 7.9% below its estimated fair value. The current EBIT per Share is ₹14.50. Metropolis Healthcare's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current EBIT per Share is ₹14.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹552.40 is trading 7.9% below its estimated GF Value™ of ₹599.61.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
EBIT per Share: ₹14.50
GF Value™: ₹599.61 vs. price of ₹552.40 (7.9% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
94GF Score
Get the complete analysis for NSE:METROPOLIS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
